In this issue of Blood, Abramson et al present follow-up data from TRANSCEND, redemonstrating robust and ongoing responses from the largest pivotal cohort of CD19 chimeric antigen receptor (CAR)-T-treated patients to date.As was seen in prior publications, the authors observed a 73% overall response rate (ORR) and a 53% complete response rate in their efficacy evaluable cohort of 257 patients.These updated data also demonstrated impressive progression-free survival (PFS) and overall survival (OS) of 40.6% and 50.5%, resp., at 2 years (previously 44.1% and 57.9%, resp., at 12 mo).With all but 2 evaluable patients having completed the 2-yr study period, this translates to a median OS of 27.3 mo, with median follow-up for survival of 29.3 mo.Although direct comparison between clin. trials is difficult because of differing patient populations and design, these results compare favorably to contemporary pivotal trials of CD19-directed CAR-T for non-Hodgkin lymphoma (NHL) with axicabtagene ciloleucel (axi-cel) in the ZUMA-1 trial and tisagenlecleucel (tisa-cel) in the JULIET trial.